A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain

PharmacoEconomics

Volumn 23, Issue 3, 2005, Pages 275-287

  Tárraga López, Pedro J ^a,f   Celada Rodríguez, Ángel ^b   Cerdán Oliver, Miguel ^a   Solera Albero, Juan ^c   Ocaña López, José M ^c   López Cara, Mateo A ^d   De Miguel Clave, Jaime ^e  

^a Zone 6 Primary Care Center   (Spain)

^b Casas Ibáñez Primary Care Center   (Spain)

^c Medical Center in Alcaraz   (Spain)

^d Tarazona Primary Care Center   (Spain)

^e Belmonte Primary Care Center   (Spain)

^f Belmonte Primary Care Center ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; SMOKING; SPAIN;

AGED; CHOLESTEROL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SPAIN; TREATMENT OUTCOME;

EID: 18644363170     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523030-00007     Document Type: Article

References (55)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1938; 41: 155-78
2. García Gil C, Cortés M. Comparación de las tendencias de mortalidad por enfermedades isquémicas del corazón y otras cardiovasculares entre España y otros países desarrollados 1970-1980. Med Clin (Barc) 1989; 93: 790-8
3. World Health Organization. World health statistics annual 1990. Geneva: WHO, 1991
4. Olalla MT, Almazán J, Sierra MJ, et al. Mortalidad por enfermedad isquémica del corazón. Bol Epidemiol Semanal 1996; 4: 213-9
5. Banegas JR, Rodríguez Artalejo F, Rodríguez Pérez P, et al. Recent coronary heart disease mortality trends in Spain. Int J Epidemiol 1990; 19: 761-2
6. Banegas JR, Rodríguez F, Villar F, et al. Perspectiva epidemiológica del riesgo en España. Iberoamerican J Epidemiol 1996; 1: 40-5
7. Villar E, Banegas JR, Rodríguez Artalejo F, et al. Mortalidad cardiovascular en España y sus comunidades autónomas. Med Clin (Barc) 1998; 110: 321-7
8. Sociedad Española de Arteriosclerosis. Sociedad Española de Medicina Interna y Liga para Lucha contra la Hipertensión Arterial. Recommendations for the primary prevention of cardiovascular disease. Clin Invest Arteriosclerosis 2000; 12 (3): 125-52
9. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46-51
10. Keys A. Coronary heart disease in seven countries. Circulation 1970; 41: 186-98
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
13. Sucks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after cardial infarctions in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
14. Grundy SM. Statin trials on goals of cholesterol lowering therapy. Circulation 1998; 97: 1436-9
15. Plaza I, Villar Álvarez F, Mata López P, et al. Control de la Colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. Rev Esp Cardiol 2000; 53: 815-37
16. Pinto Sala X. Factores que condicionan la efectividad y las indicaciones de las estatinas en prevencion cardiovascular. Aten Primaria 1999; 23 (4): 228-34
17. Simvastatin cost-effective in secondary prevention [letter]. Scrip Mag 1995; 2013: 30
18. Schwartz JS, Boccuzzi SJ, Murray JF, et al. Cost effectiveness of LDL-c reduction in Medicare managed care cHDL patients: implication from the Scandinavian Simvastatin Survival Study (4S) [abstracts 767-2]. J Am Coll Cardiol 1997; 29 Suppl. 2: 226
19. Reckless JPD. Cost implications of lipid lowering treatments. Pharmacoeconomics 1994; 6: 310-23
20. Goldmar L, Garber AM, Grover SA, et al. Task Force G. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27: 964-1047
21. Working Group on Acute Purchasing. Statin therapy/HMG CoA reductase inhibitor treatment in the prevention of coronary heart disease. Sheffield: Trent Institute for Health Services Research University of Sheffield, 1996
22. Banegas JR, Villar F, Martín-Moreno JM, et al. Relevancia de la mortalidad por enfermedades circulatorias en España. Rev Clin Esp 1992; 190: 321-7
23. Ashraf T, Hay JW, Pitt B, et al. CE of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78 (4): 409-14
24. Johanneson M, Jonsson B, Kjekshus J, et al. CE of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336 (5): 332-6
25. Szucs TD. Resource utilisation in the management of dyslipidaemia. Pharmacoeconomics 1998; 14 Suppl. 3: 11-8
26. General Council of Official Pharmaceuticals Associations. Catalog of Medicinal Products. Madrid, 2001
27. Gispert R, Brosa M. Base de Datos de Costes Sanitarios SOIKOS, 2001. Ver 1.3
28. Official College of Physicians of Barcelona (COMB). Nomenclator rates. Barcelona, 2001
29. McKenney JM. The costs of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. Pharmacoeconomics 1998; 14 Suppl. 3: 19-28
30. Banegas JR, Villar F, Pérez C, et al. Estudio epidemioló gico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Pub 1993; 67: 419-55
31. Jones P, Kafonek S, Laurora I, et al. Comparative study relationship doses-efficacy of atorvastatin versus pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (CURVES study). Am J Cardiol 1998; 81: 582-7
32. Badía X, Rovira J. Evaluación económica de medicamentos. Madrid: Luzán 5, 1994
33. Sacristán JA, Soto J, Galende S. Farmacoeconomía: el cálcule de la eficiencia. Med Clin (Barc) 1994; 103: 143-9
34. Antoñanzas F. Evaluación economica aplicada al campo de los medicamentos. Características y metodología. En: Sacristán J, Badía X, Rovira J, editores. Farmacoeconomía: evaluación económica de medicamentos. Madrid: Editores Médicos, 1995: 31-47
35. Drammond MF, Stoddent GL, Torrance GN. Análisis de coste: método para la evaluación económica de los programas de atención a la salud. Madrid: Diaz de Santos, 1993: 61-90
36. Martens L, Ruthen F, Erkelens D, et al. Clinical benefits and CE of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990; 65: 27F-32E
37. Black D, Davidson M, Noren M, et al. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Pharmacoeconomics 1997; 12: 278-35
38. Nash DT. Meeting National cholesterol education goals in clinical practice: a comparison of lovastatin and fluvastatin in primary prevention. Am J Cardiol 1996; 78 Suppl. 6A: 26-31
39. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and woman with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
40. Hilleman D, Heineman S, Foral P. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2000; 20 (7): 819-22
41. Hilleman D, Phillips J, Mohiuddin S, et al. A population based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin Ther 1999; 21: 536-62
42. Cox E, Griffis D. Critical evaluation of a CE analysis of four HMG-CoA reductase inhibitors. Formulary 1999; 34: 1041-7
43. Cobos A, Jovell A, Garcia-Altés A, et al. Which statin is most efficient for the treatment of hypercholesterolemia? A CE analysis. Clin Ther 1999; 21 (11): 1924-36
44. Huse D, Russell M, Miller J, et al. CE of statins. Am J Cardiol 1998; 52: 1357-63
45. Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the surrogate marker cost-efficacy (SmaC) Study. Clin Ther 1999; 21: 1788-96
46. Gómez-Gerique JA. Pharmacoeconomics evaluation of lowering of cholesterol with inhibitors of HMG-CoA reductase (statins) in hypercholesterolemia. Clin Invest Arteriosclero 2001; 13 (6): 241-52
47. Hilleman DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2000; 20 (7): 819-22
48. Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA inhibitor in patients with coronary artery disease. Pharmacotherapy 2001; 21 (4): 410-5
49. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients, a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998; 14 (1): 59-70
50. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atheroesclerosis Society LDL-C Target, comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest 1999; 17 (3): 185-93
51. Russell MV, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacocol 2001; 8 (1): 9-16
52. Lucas BD, Sanoski CA, Ito MK, et al. CE of statins in a cohort of 5436 patients [abstract]. J Clin Pharmacol 2001; 41 (9): 1029
53. Domingo E, Macaya C, Fernandez I, et al. A pharmacoeconomic evaluation of aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease [abstract]. Value Health 2002; 5 (6): 486
54. Rufo P, Campanella S, Bustacchini S, et al. Economic evaluation of atorvastatin versus revascularization treatment study (Avert): an Italian customization [abstract]. Value Health 2002; 5 (6): 480
55. Mantovani LG, Rufo P, Bustacchini S, et al. Economic evaluation of primary prevention of CVD events with Atorvastatin: an Italian Perspective [abstract]. Value Health 2002; 5 (6): 487